HRT Financial’s Kiniksa Pharmaceuticals KNSA Stock Holding History

HRT Financial’s Portfolio KNSA Stock Details KNSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-51,964	Closed	-$1.44M	–	3289
2025 Q2	$1.44M	Buy	+51,964	New	+$1.32M	0.01%	1077
2025 Q1	–	Sell	-11,668	Closed	-$230K	–	2974
2024 Q4	$230K	Sell	11,668 -9,023	-44%	-$206K	﹤0.01%	1855
2024 Q3	$517K	Buy	20,691 +9,616	+87%	+$234K	﹤0.01%	1571
2024 Q2	$206K	Buy	+11,075	New	+$207K	﹤0.01%	1648
2024 Q1	–	Sell	-74,866	Closed	-$1.31M	–	2710
2023 Q4	$1.31M	Buy	+74,866	New	+$1.23M	0.01%	858
2023 Q1	–	Sell	-39,751	Closed	-$595K	–	2843
2022 Q4	$595K	Buy	+39,751	New	+$579K	0.01%	1301
2022 Q2	–	Sell	-58,874	Closed	-$585K	–	3329
2022 Q1	$585K	Buy	+58,874	New	+$624K	﹤0.01%	1523
2021 Q4	–	Sell	-18,869	Closed	-$214K	–	3646
2021 Q3	$214K	Buy	+18,869	New	+$246K	﹤0.01%	2643
2020 Q1	–	Sell	-32,300	Closed	-$357K	–	1075
2019 Q4	$357K	Buy	+32,300	New	+$281K	0.02%	671

Other funds holding KNSA

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

HRT Financial's KNSA Position: Q3 2025 in Review

HRT Financial sold out of Kiniksa Pharmaceuticals (KNSA) in Q3 2025, closing a stake of 51,964 shares — an estimated $1.44M sold.

HRT Financial first reported a position in KNSA in Q4 2019 and held it in 9 quarters. The position peaked at $1.44M in Q2 2025. 204 funds tracked by Wall St. Rank hold KNSA as of Q3 2025.

HRT Financial reported no remaining Kiniksa Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
HRT Financial sold 51,964 Kiniksa Pharmaceuticals shares in Q3 2025, an estimated $1.44M.
HRT Financial first reported a position in Kiniksa Pharmaceuticals in Q4 2019 and held it in 9 quarters.
HRT Financial's Kiniksa Pharmaceuticals position peaked at $1.44M in Q2 2025.
204 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q3 2025.

Based on HRT Financial's 13F filing for Q3 2025, filed 14 Nov 2025.